Handelen G1 Therapeutics - GTHX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.05 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
G1 Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 2.79 |
| Open* | 2.85 |
| 1-Jaarlijkse Verandering* | -35.52% |
| Dagelijks bereik* | 2.77 - 2.86 |
| 52 wekelijks bereik | 2.38-17.49 |
| Weekgemiddelde volume (10 dagen) | 905.15K |
| Gemiddeld volume (3 maanden) | 18.90M |
| Marktkapitalisatie | 144.65M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 51.66M |
| Omzet | 57.35M |
| EPS | -2.78 |
| Dividend (opbrengst %) | N/A |
| Beta | 1.93 |
| Volgende inkomsten datum | Aug 1, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 7, 2023 | 2.83 | 0.06 | 2.17% | 2.77 | 2.86 | 2.76 |
| Jun 6, 2023 | 2.79 | 0.07 | 2.57% | 2.72 | 2.85 | 2.70 |
| Jun 5, 2023 | 2.78 | -0.03 | -1.07% | 2.81 | 2.86 | 2.71 |
| Jun 2, 2023 | 2.58 | 0.10 | 4.03% | 2.48 | 2.63 | 2.48 |
| Jun 1, 2023 | 2.51 | -0.02 | -0.79% | 2.53 | 2.56 | 2.43 |
| May 31, 2023 | 2.52 | -0.07 | -2.70% | 2.59 | 2.70 | 2.52 |
| May 30, 2023 | 2.63 | 0.01 | 0.38% | 2.62 | 2.73 | 2.58 |
| May 26, 2023 | 2.59 | -0.05 | -1.89% | 2.64 | 2.64 | 2.58 |
| May 25, 2023 | 2.65 | -0.15 | -5.36% | 2.80 | 2.80 | 2.63 |
| May 24, 2023 | 2.79 | -0.07 | -2.45% | 2.86 | 2.89 | 2.75 |
| May 23, 2023 | 2.87 | 0.03 | 1.06% | 2.84 | 3.04 | 2.80 |
| May 22, 2023 | 2.85 | -0.01 | -0.35% | 2.86 | 2.89 | 2.80 |
| May 19, 2023 | 2.84 | 0.06 | 2.16% | 2.78 | 2.89 | 2.77 |
| May 18, 2023 | 2.76 | 0.00 | 0.00% | 2.76 | 2.84 | 2.70 |
| May 17, 2023 | 2.75 | 0.06 | 2.23% | 2.69 | 2.77 | 2.60 |
| May 16, 2023 | 2.69 | -0.11 | -3.93% | 2.80 | 2.84 | 2.67 |
| May 15, 2023 | 2.90 | 0.22 | 8.21% | 2.68 | 2.94 | 2.68 |
| May 12, 2023 | 2.68 | -0.09 | -3.25% | 2.77 | 2.82 | 2.63 |
| May 11, 2023 | 2.75 | -0.13 | -4.51% | 2.88 | 2.96 | 2.72 |
| May 10, 2023 | 2.89 | -0.05 | -1.70% | 2.94 | 3.16 | 2.77 |
G1 Therapeutics Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Thursday, June 15, 2023 | ||
| Tijd (UTC) (UTC) 11:30 | Land US
| Evenement G1 Therapeutics Inc Annual Shareholders Meeting G1 Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 23, 2023 | ||
| Tijd (UTC) (UTC) 11:30 | Land US
| Evenement G1 Therapeutics Inc Annual Shareholders Meeting G1 Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
| Tuesday, August 1, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q2 2023 G1 Therapeutics Inc Earnings Release Q2 2023 G1 Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Tuesday, October 31, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q3 2023 G1 Therapeutics Inc Earnings Release Q3 2023 G1 Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 51.301 | 31.476 | 45.285 | 0 | 0 |
| Inkomsten | 51.301 | 31.476 | 45.285 | 0 | 0 |
| Totale bedrijfskosten | 187.479 | 173.733 | 141.761 | 129.041 | 89.286 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 101.033 | 96.491 | 69.445 | 40.648 | 18.603 |
| Onderzoek & Ontwikkeling | 82.698 | 75.426 | 72.316 | 88.393 | 70.683 |
| Bedrijfsresultaat | -136.178 | -142.257 | -96.476 | -129.041 | -89.286 |
| Overige, Netto | 0.003 | -0.546 | -0.542 | 6.594 | 3.998 |
| Netto inkomen voor belastingen | -145.859 | -147.427 | -97.844 | -122.447 | -85.288 |
| Netto inkomen na belastingen | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
| Netto inkomen voor extra. Posten | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
| Netto inkomen | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
| Total Adjustments to Net Income | 0 | 0 | |||
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
| Verwateringsaanpassing | |||||
| Verwaterd Netto Inkomen | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
| Verwaterd Gewogen Gemiddelde Aandelen | 43.6261 | 41.9434 | 37.878 | 37.4993 | 33.3167 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -3.38235 | -3.53696 | -2.62036 | -3.26532 | -2.55992 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Verwaterde Genormaliseerde Winst per Aandeel | -3.38235 | -3.54005 | -2.62036 | -3.26532 | -2.55992 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -9.684 | -4.624 | -0.826 | ||
| Kosten van opbrengsten, totaal | 3.748 | 2.016 | |||
| Brutowinst | 47.553 | 29.46 | |||
| Ongebruikelijke uitgaven (inkomsten) | -0.2 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 12.946 | 10.25 | 23.576 | 10.573 | 6.902 |
| Inkomsten | 12.946 | 10.25 | 23.576 | 10.573 | 6.902 |
| Kosten van opbrengsten, totaal | 1.459 | 0.992 | 1.111 | 0.976 | 0.669 |
| Brutowinst | 11.487 | 9.258 | 22.465 | 9.597 | 6.233 |
| Totale bedrijfskosten | 38.692 | 41.137 | 45.124 | 47.535 | 53.683 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 21.753 | 23.558 | 24.432 | 25.716 | 26.709 |
| Onderzoek & Ontwikkeling | 15.48 | 16.587 | 19.581 | 20.843 | 26.305 |
| Bedrijfsresultaat | -25.746 | -30.887 | -21.548 | -36.962 | -46.781 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -2.373 | -2.518 | -2.553 | -2.357 | -2.256 |
| Overige, Netto | 0.524 | 0.237 | 0.048 | -0.127 | -0.155 |
| Netto inkomen voor belastingen | -27.595 | -33.168 | -24.053 | -39.446 | -49.192 |
| Netto inkomen na belastingen | -27.595 | -33.649 | -25.272 | -39.446 | -49.192 |
| Netto inkomen voor extra. Posten | -27.595 | -33.649 | -25.272 | -39.446 | -49.192 |
| Netto inkomen | -27.595 | -33.649 | -25.272 | -39.446 | -49.192 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -27.595 | -33.649 | -25.272 | -39.446 | -49.192 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -27.595 | -33.649 | -25.272 | -39.446 | -49.192 |
| Verwaterd Netto Inkomen | -27.595 | -33.649 | -25.272 | -39.446 | -49.192 |
| Verwaterd Gewogen Gemiddelde Aandelen | 51.6479 | 46.309 | 42.7993 | 42.7077 | 42.6872 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.53429 | -0.72662 | -0.59048 | -0.92363 | -1.15238 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.53429 | -0.72662 | -0.59048 | -0.92363 | -1.15238 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 179.5 | 243.565 | 216.392 | 271.003 | 370.133 |
| Geldmiddelen en kortetermijnbeleggingen | 145.07 | 221.186 | 207.306 | 269.208 | 369.29 |
| Geldmiddelen & Equivalenten | 94.594 | 221.186 | 207.306 | 269.208 | 369.29 |
| Prepaid Expenses | 7.094 | 13.157 | 8.786 | 1.732 | 0.843 |
| Total Assets | 187.965 | 254.094 | 228.552 | 284.831 | 371.27 |
| Property/Plant/Equipment, Total - Net | 7.951 | 9.048 | 10.508 | 13.391 | 1.137 |
| Property/Plant/Equipment, Total - Gross | 9.777 | 10.344 | 11.335 | 14.068 | 1.459 |
| Accumulated Depreciation, Total | -1.826 | -1.296 | -0.827 | -0.677 | -0.322 |
| Total Current Liabilities | 35.588 | 27.613 | 23.443 | 19.769 | 12.362 |
| Accounts Payable | 7.431 | 2.897 | 3.572 | 3.684 | 3.377 |
| Accrued Expenses | 26.692 | 24.295 | 17.474 | 16.085 | 8.985 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.465 | 0.421 | 2.397 | ||
| Total Liabilities | 119.218 | 110.553 | 51.201 | 29.304 | 12.45 |
| Total Long Term Debt | 77.015 | 75.19 | 19.893 | 0 | 0 |
| Total Equity | 68.747 | 143.541 | 177.351 | 255.527 | 358.82 |
| Redeemable Preferred Stock | |||||
| Common Stock | 0.005 | 0.004 | 0.004 | 0.004 | 0.004 |
| Retained Earnings (Accumulated Deficit) | -732.018 | -584.459 | -436.107 | -336.853 | -214.406 |
| Treasury Stock - Common | -0.008 | -0.008 | -0.008 | -0.008 | -0.008 |
| Total Liabilities & Shareholders’ Equity | 187.965 | 254.094 | 228.552 | 284.831 | 371.27 |
| Total Common Shares Outstanding | 51.4994 | 42.5621 | 38.1141 | 37.6116 | 37.2421 |
| Other Liabilities, Total | 6.615 | 7.75 | 7.865 | 9.535 | 0.088 |
| Additional Paid-In Capital | 800.768 | 728.004 | 613.462 | 592.384 | 573.23 |
| Other Current Assets, Total | 0.063 | 0.063 | 0.063 | 0.063 | |
| Other Long Term Assets, Total | 0.514 | 1.481 | 1.652 | 0.437 | |
| Totale Vorderingen, Netto | 11.094 | 5.688 | 0.237 | ||
| Accounts Receivable - Trade, Net | 11.094 | 5.688 | 0.237 | ||
| Long Term Debt | 77.015 | 75.19 | 19.893 | ||
| Total Inventory | 16.179 | 3.471 | |||
| Korte Termijn Investeringen | 50.476 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 153.965 | 179.5 | 157.465 | 177.1 | 208.336 |
| Geldmiddelen en kortetermijnbeleggingen | 116.317 | 145.07 | 122.982 | 143.957 | 183.02 |
| Geldmiddelen & Equivalenten | 68.237 | 94.594 | 93.238 | 143.957 | 183.02 |
| Totale Vorderingen, Netto | 16.025 | 11.094 | 10.521 | 10.787 | 7.615 |
| Accounts Receivable - Trade, Net | 16.025 | 11.094 | 10.521 | 10.787 | 7.615 |
| Total Inventory | 15.543 | 16.179 | 13.95 | 14.014 | 7.86 |
| Prepaid Expenses | 6.017 | 7.094 | 9.949 | 8.279 | 9.778 |
| Other Current Assets, Total | 0.063 | 0.063 | 0.063 | 0.063 | 0.063 |
| Total Assets | 161.957 | 187.965 | 166.573 | 186.879 | 218.239 |
| Property/Plant/Equipment, Total - Net | 7.564 | 7.951 | 8.365 | 8.773 | 8.673 |
| Property/Plant/Equipment, Total - Gross | 9.522 | 9.777 | 10.054 | 10.323 | 10.084 |
| Accumulated Depreciation, Total | -1.958 | -1.826 | -1.689 | -1.55 | -1.411 |
| Other Long Term Assets, Total | 0.428 | 0.514 | 0.743 | 1.006 | 1.23 |
| Total Current Liabilities | 33.69 | 35.588 | 37.134 | 37.252 | 34.983 |
| Accounts Payable | 5.38 | 7.431 | 8.442 | 9.349 | 11.018 |
| Accrued Expenses | 22.767 | 26.692 | 27.251 | 26.599 | 22.577 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 5.543 | 1.465 | 1.441 | 1.304 | 1.388 |
| Total Liabilities | 116.969 | 119.218 | 120.608 | 120.554 | 118.107 |
| Total Long Term Debt | 77.47 | 77.015 | 76.558 | 76.102 | 75.646 |
| Long Term Debt | 77.47 | 77.015 | 76.558 | 76.102 | 75.646 |
| Other Liabilities, Total | 5.809 | 6.615 | 6.916 | 7.2 | 7.478 |
| Total Equity | 44.988 | 68.747 | 45.965 | 66.325 | 100.132 |
| Common Stock | 0.005 | 0.005 | 0.004 | 0.004 | 0.004 |
| Additional Paid-In Capital | 804.604 | 800.768 | 744.338 | 739.426 | 733.787 |
| Retained Earnings (Accumulated Deficit) | -759.613 | -732.018 | -698.369 | -673.097 | -633.651 |
| Treasury Stock - Common | -0.008 | -0.008 | -0.008 | -0.008 | -0.008 |
| Total Liabilities & Shareholders’ Equity | 161.957 | 187.965 | 166.573 | 186.879 | 218.239 |
| Total Common Shares Outstanding | 51.6593 | 51.4994 | 42.8971 | 42.7275 | 42.7055 |
| Korte Termijn Investeringen | 48.08 | 50.476 | 29.744 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
| Geldmiddelen uit Operationele Activiteiten | -128.62 | -132.108 | -83.742 | -99.571 | -74.307 |
| Geldmiddelen uit Operationele Activiteiten | 0.53 | 0.469 | 0.582 | 0.356 | 0.175 |
| Niet-Geldelijke Posten | 23.716 | 24.613 | 19.006 | 16.449 | 10.233 |
| Veranderingen in het Operationeel Kapitaal | -5.307 | -8.838 | -4.076 | 6.071 | 0.573 |
| Geldmiddelen uit Investeringsactiviteiten | -50.529 | 0 | 0.152 | -2.716 | -0.709 |
| Kapitaaluitgaven | -0.506 | 0 | -2.716 | -0.709 | |
| Geldmiddelen uit Financieringsactiviteiten | 52.495 | 145.863 | 21.688 | 2.705 | 340.494 |
| Financiering van Cash Flow Posten | -0.043 | -1.411 | -0.62 | 0 | -0.892 |
| Uitgifte (Aflossing) van aandelen, netto | 52.538 | 92.274 | 2.308 | 2.705 | 341.386 |
| Nettowijziging in Geldmiddelen | -126.654 | 13.755 | -61.902 | -99.582 | 265.478 |
| Contant Betaalde Rente | 7.924 | 2.908 | 0.997 | ||
| Overige Cash Flow investeringsposten, Totaal | -50.023 | 0 | 0.152 | ||
| Uitgifte (Aflossing) van Schulden, Netto | 0 | 55 | 20 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -27.595 | -147.559 | -113.91 | -88.638 | -49.192 |
| Cash From Operating Activities | -29.053 | -128.62 | -97.988 | -76.741 | -38.184 |
| Cash From Operating Activities | 0.132 | 0.53 | 0.393 | 0.254 | 0.115 |
| Non-Cash Items | 4.75 | 23.716 | 18.876 | 13.433 | 7.071 |
| Cash Interest Paid | 2.512 | 7.924 | 5.61 | 3.537 | 1.716 |
| Changes in Working Capital | -6.34 | -5.307 | -3.347 | -1.79 | 3.822 |
| Cash From Investing Activities | 2.91 | -50.529 | -30.167 | -0.506 | 0 |
| Capital Expenditures | -0.506 | -0.506 | -0.506 | ||
| Cash From Financing Activities | -0.214 | 52.495 | 0.145 | 0.018 | 0.018 |
| Financing Cash Flow Items | -0.215 | -0.043 | 0 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 0.001 | 52.538 | 0.145 | 0.018 | 0.018 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
| Net Change in Cash | -26.357 | -126.654 | -128.01 | -77.229 | -38.166 |
| Other Investing Cash Flow Items, Total | 2.91 | -50.023 | -29.661 | 0 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Eshelman Ventures LLC | Corporation | 8.7418 | 4516074 | 1076923 | 2023-03-31 | |
| MedImmune Ventures, Inc. | Venture Capital | 5.7116 | 2950630 | 0 | 2023-03-31 | LOW |
| Fisher Investments | Investment Advisor/Hedge Fund | 5.2743 | 2724710 | -84734 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8322 | 1979728 | 64930 | 2023-03-31 | LOW |
| JP Morgan Asset Management | Investment Advisor | 3.5808 | 1849847 | 98867 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2765 | 1176054 | -15433 | 2023-03-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.8672 | 964592 | 686025 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 1.694 | 875134 | -796725 | 2023-03-31 | HIGH |
| Marshall Wace LLP | Investment Advisor/Hedge Fund | 1.4777 | 763376 | -231612 | 2023-03-31 | HIGH |
| Raymond James & Associates, Inc. | Research Firm | 1.4468 | 747411 | 248508 | 2023-03-31 | LOW |
| BofA Global Research (US) | Research Firm | 1.168 | 603418 | 347052 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.8575 | 442975 | -204125 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8486 | 438394 | 83855 | 2023-03-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 0.8317 | 429639 | -15068 | 2023-03-31 | LOW |
| Tekla Capital Management LLC | Investment Advisor | 0.8205 | 423869 | 0 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.7317 | 377983 | -345120 | 2023-03-31 | HIGH |
| Susquehanna International Group, LLP | Investment Advisor | 0.6219 | 321273 | -56519 | 2023-03-31 | HIGH |
| Woodline Partners LP | Hedge Fund | 0.5824 | 300874 | -728093 | 2023-03-31 | HIGH |
| XTX Markets LLC | Investment Advisor | 0.5697 | 294292 | 192010 | 2023-03-31 | HIGH |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.5483 | 283235 | 190189 | 2023-03-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
G1 Therapeutics Company profile
Over G1 Therapeutics
G1 Therapeutics, Inc. is een biofarmaceutisch bedrijf in een commerciële fase. Het bedrijf richt zich op de ontwikkeling en commercialisering van kleine moleculegeneesmiddelen voor de behandeling van kankerpatiënten. Het voornaamste product van de Vennootschap, COSELA (trilaciclib), is een therapie die ontworpen is om hematopoietische stam- en progenitorcellen (HSPC's) in het beenmerg te helpen beschermen tegen door chemotherapie veroorzaakte myelosuppressie door CDK4/6 tijdelijk te remmen bij patiënten met kleincellige longkanker in een vergevorderd stadium (ES-SCLC). Lerociclib is een gedifferentieerde orale CDK4/6-remmer in klinische fase, voor gebruik in combinatie met andere gerichte therapieën bij meerdere oncologische indicaties. Rintodestrant, een orale selectieve oestrogeenreceptor degrader (SERD), voor gebruik als monotherapie en in combinatie met CDK4/6-remmers, aanvankelijk Ibrance (palbociclib), voor de behandeling van oestrogeenreceptor-positieve (ER+), humane epidermale groeifactor receptor 2 (HER2)-borstkanker, bevindt zich in het klinische stadium.
| Industry: | Bio Therapeutic Drugs |
700 Park Offices Drive
Suite 200
RESEARCH TRIANGLE PARK
NORTH CAROLINA 27709
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen